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INTRODUCTION
Type 2B VWD is caused by gain-of-function mutations in exon
28 of the VWF gene encoding the binding site for platelet GPIb,
leading to increased affinity of VWF to platelet GPIb with
subsequent increased clearance of HMWM in plasma [1–3]. The
multimeric structure of VWF allows it to function as a molecular
bridge between the subendothelial matrix and the platelet GPIb
receptor complex [3]. One of the characteristic findings in type 2B
VWD is the relative loss of VWF HMWM in plasma, which is
believed to be due to increased clearance ofVWF–platelet complex.
Here we describe a patient with type 2B VWD with characteristic
loss of VWF HMWM and a normal platelet count initially.
Interestingly, his HMWM appeared when he developed ITP, and
disappeared again when his platelet count increased. Possible
causes leading to the restoration of his HMWM are discussed.
CASE REPORT
The patient is a 13-year-old African American male who was
diagnosed with type 2BVWD at 5 years of age. He presented with a
history of frequent epistaxis since 6 months of age. Laboratory
evaluation at diagnosis was characteristic of type 2B VWD,
including decreased VWF activity (24%), VWF antigen (0.32 U),
and FVIII activity (45%); increased low dose ristocetin-induced
platelet aggregation (RIPA) and absence of VWF HMWM
(Fig. 1A). He required periodic antihemophilic factor/von Wille-
brand factor complex (Humate-P, manufactured by ZLB Behring
Gmbh,Marburg, Germany) for the management of severe epistaxis.
His platelet count remained normal (242,000–292,000 ml1) until
8 years after the diagnosis of type 2BVWD,whenhewas found to be
thrombocytopenic during the evaluation for a traumatic lip
laceration. His platelet count nadir was 6,000 ml1 (Fig. 2). Further
evaluation revealed an increased number of megakaryocytes in his
bone marrow and autoantibodies to GPIIb/IIIa, Ib/IX and Ia/IIa in
his platelet eluates. (The test for platelet auto antibodies was
performed at theBloodCenter ofWisconsin as previously described
[4].) As ITP was suspected, he received anti-D immunoglobulin
(WinRho, manufactured by Cangene Corporation, Winnipeg,
Canada), prednisone and intravenous immunoglobulin therapy over
the following 2 months with poor response. His platelet counts
ranged from 6,000 to 24,000 ml1. Surprisingly, a repeat VWDwork
up 10 weeks after he developed thrombocytopenia was within
normal limits. VWF activity was 66%, VWF antigen was 77%,
FVIII activity was 93%, and VWFmultimeric analysis revealed the
presence of a full range ofVWFmultimers (Fig. 1B).Of note, he had
not received anyVWF-containingproducts in theprevious2months.
To reconfirm the diagnosis of type 2B VWD, a GPIb binding assay
was performed as described [5], and revealed increased platelet
GPIb binding to VWF, consistent with his diagnosis of type 2B
VWD. Additionally, he had a point mutation (4022G>A) in exon
28 of VWF gene known to be associated with type 2BVWD [6]. His
ADAMTS-13 activity was normal and there were no ADAMTS-13
inhibitors. His platelet count slowly increased to 44,000 ml1
5 months following the diagnosis of ITP (Fig. 2). At that time, his
VWD indices, including VWF antigen (52%), activity (59%), and
FVIII activity (57%) again decreased; VWFmultimeric distribution
was abnormal with the loss of HMWM but the presence of
intermediate size multimers (Fig. 1C), which was different from his
VWF multimer pattern at diagnosis. His platelet count increased to
66,000 ml1 approximately 2 years after hewas diagnosed with ITP.
DISCUSSION
We report a patient with concurrent ITP and type 2B VWD. The
normalization of his VWD indices and restoration of his VWF
HMWM following the onset of thrombocytopenia are of particular
interest. Type 2BVWD is characterized by the relative loss of VWF
HMWM in plasma, which is believed to be due to spontaneous
binding ofmutatedVWFHMWMto platelets, which causes platelet
aggregation followed by removal of the VWF–platelet aggregates.
This leads to the loss of HMWM and thrombocytopenia [1,7]. The
We report a case of concurrent type 2B von Willebrand disease
(VWD) and immune thrombocytopenia (ITP). The patient had
characteristic loss of von Willebrand factor (VWF) high molecular
weight multimers (HMWM) but a normal platelet count in the initial
8 years after diagnosis of type 2B VWD. When he developed severe
thrombocytopenia, however, both his VWD indices and VWF
HMWM normalized. As his platelet count increased, he again lost
the HMWM and his VWD indices decreased. These results suggest
that the severe thrombocytopenia led to decreased clearance of
VWF, especially the HMWM. Pediatr Blood Cancer 2008;51:416–
418.  2008 Wiley-Liss, Inc.
Key words: hemostasis; ITP; thrombocytopenia; VWD; VWF
 2008 Wiley-Liss, Inc.
DOI 10.1002/pbc.21593
——————
1Division of Hematology/Oncology, Children’s Hospital of Michigan,
Wayne State University, Detroit, Michigan; 2Department of Pediatrics,
Hurley Medical Center, Flint, Michigan
*Correspondence to: Zhihong J. Wang, Division of Hematology/
Oncology, Children’s Hospital of Michigan, 3901 Beaubien, Detroit,
MI 48201. E-mail: jwang2@med.wayne.edu
Received 4 October 2007; Accepted 18 March 2008
patient had a characteristic loss of VWF HMWMwhen his platelet
count was normal, however, his HMWM were restored when he
developed severe thrombocytopenia, and disappeared again when
his platelet count increased. This suggests that the reduced number
of platelets led to decreased clearance of VWF and restoration of
VWF HMWM and provides strong evidence that the loss of VWF
HMWM and thrombocytopenia in type 2B VWD is due to the
increased clearance of platelet–VWF complexes (as this patient’s
VWF multimer pattern was restored to normal when there were
essentially no platelets present).
Thrombocytopenia is a frequent finding in type 2B VWD and is
believed to be due to increased clearance of VWF–platelet
complexes [8]. However, the thrombocytopenia in our patient is
different from the thrombocytopenia in type 2BVWD. First, hewas
not thrombocytopenic in the initial 8 years of follow-up. Second,
when his thrombocytopenia appeared, it was severe and associated
with restoration of previously absent VWD HMWM. Additionally,
the presence of several autoantibodies to platelets supports the
diagnosis of ITP. While his poor initial response to treatment is not
typical of ITP, it is not uncommon in this age group. Furthermore,
since increased clearance of VWF–platelet complex leads to
thrombocytopenia in type 2B VWD, it is also possible that his
underlying type 2B VWD may have masked his initial response to
treatment.
Although speculative, another possibility is that the autoanti-
body to platelet GPIb present in his plasma has interfered with the
binding ofVWF to platelets and led to the decreased consumption of
VWF. The interaction between VWF and GPIb is mediated by
specific regions of both components [9]. Cooney et al. proposed that
the VWF GPIb binding domain can adopt either a discrete ‘‘on’’ or
‘‘off’’ conformation [10]. Naı̈ve VWF in the circulation is
predominantly in the ‘‘off’’ conformation and does not associate
with platelets. In type 2BVWFmutants, VWF is locked in the ‘‘on’’
conformation, which heightens VWF–platelet binding and sponta-
neous platelet aggregation, leading to increased clearance of VWF
HMWM [10].We speculate that in the patient we describe, platelet-
bound GPIb antibody may have caused the change of VWF
conformation from the locked ‘‘on’’ to ‘‘off’’ status andmodified the
gain-of-function defect, and therefore, led to reduced affinity of
VWF for platelets and decreased the clearance of VWF HMWM.
Some published reports support this possibility [11,12]. The
immune inhibition of RIPA by rabbit antisera to a human platelet
antigen was described by Nachman et al. [11], and the inhibitory
effect of antibodies on mutated VWF-induced platelet aggregation
was further confirmed by the study of De Romeuf et al. [12]. Using
recombinant VWF (rVWF) reproducing four type 2B VWD
missense mutations, they have shown that both the binding of
mutated rVWFs to platelets and the platelet aggregation induced by
rVWFs are specifically inhibited by monoclonal antibodies to GPIb
or VWF [12].
In summary, we have demonstrated the restoration of VWF
HMWM in a patient with type 2B VWD following the onset of ITP.
Our observations suggest that the reduced numbers of platelets
secondary to ITP caused decreased clearance of VWF–platelet
complexes. This case report provides in vivo evidence that the loss
of VWFHMWMand thrombocytopenia in type 2BVWDare due to
increased clearance of platelet–VWF complexes.
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Fig. 1. VWF multimer analysis at diagnosis of type 2B VWD and
after the development of ITP. A: VWF multimer analysis at diagnosis.
Absence of HMWVWFmultimers was evident in the patient’s sample.
1 and 4:Normal controls; 2: patient; 3: unknown.Multimer analysis was
performed at the Mayo Clinic Coagulation Laboratory. B: VWF
multimer analysis at two and half months following the development of
ITP. Normal VWFmultimeric distribution was seen with a full range of
VWF multimers. 5: Patient; 6: normal control. Multimer analysis was
performed at theBloodCenter ofWisconsin.C: VWFmultimer analysis
5 months after the development of ITP when platelet count increased.
VWF multimeric distribution was abnormal with absence of HMWM
but presence of intermediate sizemultimers. This patternwas not typical
of type 2B vWDand differed from the pattern at diagnosis. The patient’s
platelet count at that timewas 44,000ml1. 7 and 11:Normal controls; 8:
patient; 9: type 2B VWD control; 10: large multimer control. Multimer
analysis was performed at the Blood Center of Wisconsin.
Fig. 2. Platelet count prior to and following the development of ITP.
Platelet count was normal at diagnosis and remained normal (242,000–
292,000 ml1) until the patient developed ITP 8 years after he was
diagnosed with type 2B VWD. The platelet count decreased on 27 May
2005 with a nadir of 6,000 ml1. It started increasing 3 months after he
was found thrombocytopenic and reached 66,000 ml1 in June 2007,
approximately 2 years later.
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Reversible Skeletal Changes After Treatment With Bevacizumab in a Child
With Cutaneovisceral Angiomatosis With Thrombocytopenia Syndrome
Angela R. Smith, MD,1* Jane M. Hennessy, RN, CNP,2 Margaret A. Heisel Kurth, MD,2 and Stephen C. Nelson, MD2
INTRODUCTION
Cutaneovisceral angiomatosis with thrombocytopenia (CAT)
syndrome is a rare vascular disorder that was first recognized as a
distinct entity in 2001with a description of 10 patients withmultiple
skin and gastrointestinal vascular lesions associated with minor, but
sustained thrombocytopenia. Histopathology of the vascular lesions
in CAT syndrome shows dilated thin-walled channels with
endothelial hyperplasia. The lesions have varying degrees of
dilation and endothelial hyperplasia [1]. North et al. also describe
three patients with similar clinical symptoms and histopathology,
but have termed the entity ‘‘multifocal lymphangioendothelioma-
tosis with thrombocytopenia’’ because of its histologic similarity to
benign lymphangioendothelioma which is most commonly seen as
an acquired lesion in adulthood [2].
The clinical features of CAT syndrome includemultiple, discrete
red-brown or blue skin lesions, gastrointestinal lesions and
thrombocytopenia. Unlike infantile hemangioma, the skin lesions
Cutaneovisceral angiomatosis with thrombocytopenia (CAT)
syndrome is a rare vascular disorder of the skin and gastrointestinal
tract for which there is no standard treatment. We present a case in
which a child with CAT syndrome was treated with bevacizumab, a
vascular endothelial growth factor inhibitor, and subsequently
developed asymptomatic metaphyseal bone lesions. Though not
previously described as a side effect, we hypothesize that the use of
bevacizumab in a child with active epiphyseal growth plates caused
these radiographic lesions. Because of the potential for altered
bone growth and metabolism, children receiving VEGF inhibitors
should be monitored closely for bony toxicity. Pediatr Blood Cancer
2008;51:418–420.  2008 Wiley-Liss, Inc.
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